TRUP
$26.21+0.70 (+2.74%)
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, Continental Europe, and Australia.
Recent News
Assessing Trupanion (TRUP) Valuation After Recent Weak Share Performance And Earnings Outlook
Context for Trupanion’s Recent Share Performance Trupanion (TRUP) has been drawing fresh attention after a period of weak share performance, with the stock showing negative returns over the past month, past 3 months, year to date, and over the past year. See our latest analysis for Trupanion. At a share price of $25.51, Trupanion’s recent 7 day share price return of 2.82% contrasts with a 30 day share price return decline of 12% and a 1 year total shareholder return decline of 30.64%. This...
3 Insurance Stocks Walking a Fine Line
Insurance companies serve as the backbone of risk management, providing essential protection and financial security for individuals and businesses. But worries about an economic slowdown and potential claims deterioration have kept sentiment in check, and over the past six months, the industry has tumbled by 6.1%. This drawdown was disheartening since the S&P 500 gained 1.1%.
3 Russell 2000 Stocks That Concern Us
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
Trupanion (TRUP): Buy, Sell, or Hold Post Q4 Earnings?
Shareholders of Trupanion would probably like to forget the past six months even happened. The stock dropped 33.7% and now trades at $28.77. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
1 of Wall Street’s Favorite Stock to Own for Decades and 2 That Underwhelm
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.